Select region

Press release Gothenburg, Sweden, on March 27, 2024

Getinge publishes 2023 annual report

Today, Getinge publishes its 2023 annual report including a sustainability report, summarizing a year of huge contrasts. The global medtech company’s 2023 was marked by record-breaking sales, two major acquisitions, and successful product launches, amid the continued war in Europe, quality challenges in two product segments, and persistent inflationary pressure.

"Reflecting on the dynamic landscape of 2023, we navigated through both triumphs and trials with resilience and innovation. Like many, we experienced some headwinds," says Mattias Perjos, President & CEO at Getinge.

The company routed through quality challenges in the Cardiac Assist and Cardiopulmonary segments, addressing it with focus and determination. The shortcomings were identified due to improvements in Getinge’s quality system and are being addressed throughout 2024.

“Our commitment to quality and excellence equals our dedication to sustainability,” says Mattias. “It is not something we manage separately; it is an integral part of our strategy and included in everything we do. We are making progress in our sustainability efforts, and we aim to do even more.”

In 2023, the customer loyalty to Getinge remained strong, fueled by a portfolio of innovative products and a dedicated team.

"Our customers' trust is our greatest achievement," says Mattias. "A world-leading position in several product categories is not just about our past innovations: it's about our ongoing commitment to saving and improving lives. Today, our products help save ten million lives every year, and we want to double that number.”

Looking ahead, Mattias notes that emerging trends like an ageing population, digitalization, and AI, alongside a growing emphasis on sustainability from both Getinge and its customers may come to have an impact.

“These trends present new opportunities for us to enhance our offerings and further integrate sustainability into our solutions,” he explains.

While 2023 closed with strong sales and a healthy cash flow, with margins pressured from quality costs and mix effects, Mattias looks optimistically towards 2024.

“The demand for our solutions remains robust, and the positive outlook from discussions and surveys with our customers motivates us further to keep making life-saving technology accessible for more people,” Mattias concludes.

Getinge’s 2023 annual report, including its sustainability report, is available at

Investor Relations:

Lars Mattsson, Head of Investor Relations
Phone: +46 (0)10 335 0043

Media contact:

Caroline Örmgård, Head of Public & Media Relations
Phone: +46 (0)10 335 0041

This information is information that Getinge AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 09.00 CET on March 27, 2024.

About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.